Bristol Myers Squibb (BMS) has entered into a worldwide research collaboration with Repare Therapeutics to utilise its CRISPR-enabled genome-wide synthetic lethal target discovery platform, SNIPRx®, to develop therapeutics that target specific vulnerabilities of tumours in genetically defined patient populations. The deal comes six months following the completion of BMS’ acquisition of Celgene in November 2019. Interestingly, Celgene was one of Repare’s original backers when it launched from stealth mode in June 2017.